Science 37 – Decentralised Clinical Trials Industry – Q4 2021 Update & Product Portfolio Overview – 12 October 2021

  • Private Equity
  • Healthcare
  • North America


Former Director at Science 37 Inc


  • Trends and developments in the virtual and hybrid clinical trial industry, focusing on Science
  • Patient recruitment and retention dynamics and potential cost and time savings of virtual and hybrid vs bricks-and-mortar clinical trials
  • Science 37’s software vs services offerings portfolio, including needed improvements for the latter
  • Potential M&A expectations for Science 37 and possible synergies with a CRO (contract research organisation) acquirer


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 25,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited